Loading...
 
Back to the list
Mediterr J Rheumatol 2020;31(1):84-6
Article Links
Development of an ANCA-Associated Vasculitides Patient Registry in Greece
Konstantinos Thomas1, Alexandros Panagiotopoulos1, Aggelos Banos2, Evangelia Argyriou3, Kyriaki Boki3, Dimitrios Boumpas2, Dimitrios Vassilopoulos1
Authors Information
1. Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Athens, Greece
2. Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine-Clinical Immunology-Rheumatology Unit, 4th Department of Medicine, Athens, Greece
3. Rheumatology Unit, Sismanogleio General Hospital, Athens, Greece
Keywords: vasculitis, registry, comorbidities
References
  1. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70(3):488-94.
  2. Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64(2):542-8.
  3. Thomas K, Chalkia A, Drekolias D, Christina Tsalapaki, Argyro Lazarini, Kalliopi Klavdianou, et al. AB0626 INCIDENCE OF SERIOUS INFECTIONS AND PATTERNS OF COTRIMOXAZOLE PROPHYLAXIS IN PATIENTSWITH ANCA-ASSOCIATED VASCULITIDES. Ann Rheum Dis 2019;78:1774.
  4. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363(3):221-32.
  5. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016 Sep;75(9)1583-94.
  6. Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017;28(9):2756-67.
  7. Walsh M, Merkel PA, Peh CA, Szpirt W, Guillevin L, Pusey CD, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): Protocol for a randomized controlled trial. Trials 2013;14(1).
  8. Robson J, Doll H, Suppiah R, , Flossmann O, Harper L, Höglund P, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015;74(1):177-84.
  9. Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 20111480-6.
  10. Robson JC, Dawson J, Doll H, Cronholm PF, Milman N, Kellom K, et al. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann Rheum Dis 2018;77(8):1158-65.
  11. Bajema IM, Bruijn JA, Casian A, Cid MC, Csernok E, van Daalen E, et al. The European Vasculitis Society 2016 Meeting Report. Kidney Int Rep 2017 Sep 21;2(6):1018-31.